Adaptimmune -Model ADP-A2AFP Spear -T-Cell Therapy Pipeline

Our ADP-A2AFP SPEAR T-cell product targets alpha-fetoprotein (AFP) is being investigated in an ongoing Phase 1 clinical trial for the treatment of patients with hepatocellular carcinoma (liver cancer).